Robert Bruno | Director of Clinical Operations
Abbvie Japan | Japan

Robert Bruno, Director of Clinical Operations, Abbvie Japan

Rob has durable leadership experience in global clinical trial operations, project management and quality for Phase I - IV trials in a variety of therapeutic areas (Oncology, CNS, CV, ID, Diabetes, etc.) for Big Pharma, startup Biotech firms and CROs. He has a consistent record managing cross functional teams & projects - requiring resourcefulness, sustained energy, solid analytical ability, technical understanding and exceptional communications, diplomacy & cultural literacy.

Rob joined AbbVie in 2014 as the Lead for Clinical Planning & Resource Management and later assumed the Director role for Renal & Dyslipidemia in Clinical Program Development.  He started his current assignment as Director, Clinical Operations with Japan Development,Tokyo in July 2015.  

Prior to joining AbbVie, Rob worked in a variety of capacities in large Pharma (Pfizer, BMS & Lilly), mid-size Biotechs (Targanta, Osiris) and Clinical Research Organizations (Covance, PPD & Translational Medicine India).  All roles contributed to his broad understanding of and capabilities within clinical development.

Rob received his undergraduate degree from Gettysburg College in Pennsylvania, USA.  He holds a Doctorate in Public Health, MS (Nutritional Biochem & Physiology), & MBA from Columbia University in New York.

Appearances:



Phar-East Day Two @ 11:10

Multi regional clinical trial (MRCT) harmonisation: An overview

This one hour session includes an overview presentation on MRCT in Asia, with quick 10-minute updates from Japan, Taiwan, Malaysia, Singapore and a combined 20 minutes panel session to discuss regulatory challenges from both regulator and pharma perspectives, successes so far and what can be expected in the year of 2020
 
11:00 Overview of MRCT in Asia
James Cai, VP Global Regulatory Affairs, Access & Policy, Amgen, China
 
11:10 ICH E17
Koichi Miyazaki, Senior Director, Regulatory Affairs, Asia Development Department, Daiichi Sankyo, Japan
 
11:20 Japan
Robert Bruno, Director, Clinical Program Development, Abbvie, Japan
 
11:30 Taiwan
I-Ning Tang, Senior Senior Reviewer, Center For Drug Evaluation, Taiwan
 
11:40 China
Gloria Wang, Executive Director, Clinical Development Just Biotherapeutics, China
 
11:50-12:30 Panel: Successes and future strategies to promote cross-country drug development
James Cai, VP Global Regulatory Affairs, Access & Policy, Amgen, China
I- Ning Tang, Senior Senior Reviewer, Center For Drug Evaluation, Taiwan
Robert Bruno, Director, Clinical Program Development, Abbvie, Japan
Gloria Wang, Executive Director, Clinical Development, Just Biotherapeutics, China
Koichi Miyazaki, Senior Director, Regulatory Affairs, Asia Development Department, Daiichi Sankyo, Japan

back to speakers